Monday, March 2, 2015

Biotech Investing: Merrimack (MACK) gets a shout out in Cramer's Lightning Round

Jim Cramer gave a positive vote of confidence during tonight's lightning round on Mad Money.  I've written a number of articles expressing my strong opinion (and large holding) of Merrimack.  It has a great pipeline and MM-398 should get approved for hard-to-treat pancreatic cancer later this year.

I currently hold 11,300 shares of Merrimack and no plans to buy our sell in the near future.



Merrimack Pharmaceuticals: "We like them! That was one of our spec pharma picks. We still continue to like it. I think it's in real good shape. You have a good one in Merrimack, we still like it."
 

No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com